Response to letter to the editor regarding Alqahtani et al. Article on priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?

Affiliations

¹ International Center of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.
² School of Public Health and Health Sciences, University of Massachusetts, Amherst, USA.

Comment

Enrique Seoane-Vazquez et al. Pharmacoepidemiol Drug Saf. 2016 Jun.

. 2016 Jun;25(6):745-6.

doi: 10.1002/pds.4010.

¹ International Center of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.
² School of Public Health and Health Sciences, University of Massachusetts, Amherst, USA.

No abstract available

Comment on

Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S, Seoane-Vazquez E, Rodriguez-Monguio R, Eguale T. Alqahtani S, et al. Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):709-15. doi: 10.1002/pds.3793. Epub 2015 May 27. Pharmacoepidemiol Drug Saf. 2015. PMID: 26013294
In response to Alqahtani et al. (2015 Jul; 24(7):709-15): suggesting an international regulatory harmonization for priority review drugs need further investigations.
Boucaud-Maitre D, Ropers J. Boucaud-Maitre D, et al. Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):743-4. doi: 10.1002/pds.3973. Pharmacoepidemiol Drug Saf. 2016. PMID: 27245859 No abstract available.